Compare Stocks: SCPH, MNKD, ALMS, and GLUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.77 -0.6%	$21.56	$3.76 ▼ $31.35	$1.01B	-0.81	4.39 million shs	6.38 million shs
GLUE Monte Rosa Therapeutics	$12.13 -3.7%	$16.95	$6.23 ▼ $25.77	$1.07B	1.5	1.12 million shs	1.60 million shs
MNKD MannKind	$3.54 -1.1%	$3.95	$2.23 ▼ $6.51	$1.15B	1.1	2.77 million shs	5.51 million shs
SCPH scPharmaceuticals	$5.67	$5.64	$2.20 ▼ $6.28	$302.20M	0.31	953,834 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-0.64%	-15.36%	-67.61%	-66.81%	+88.14%
GLUE Monte Rosa Therapeutics	-3.73%	-13.79%	-23.08%	-33.75%	+90.72%
MNKD MannKind	-1.12%	-5.60%	-19.36%	-10.15%	-34.32%
SCPH scPharmaceuticals	0.00%	0.00%	0.00%	0.00%	+0.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.77 -0.6%	$21.56	$3.76 ▼ $31.35	$1.01B	-0.81	4.39 million shs	6.38 million shs
GLUE Monte Rosa Therapeutics	$12.13 -3.7%	$16.95	$6.23 ▼ $25.77	$1.07B	1.5	1.12 million shs	1.60 million shs
MNKD MannKind	$3.54 -1.1%	$3.95	$2.23 ▼ $6.51	$1.15B	1.1	2.77 million shs	5.51 million shs
SCPH scPharmaceuticals	$5.67	$5.64	$2.20 ▼ $6.28	$302.20M	0.31	953,834 shs	N/A

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-0.64%	-15.36%	-67.61%	-66.81%	+88.14%
GLUE Monte Rosa Therapeutics	-3.73%	-13.79%	-23.08%	-33.75%	+90.72%
MNKD MannKind	-1.12%	-5.60%	-19.36%	-10.15%	-34.32%
SCPH scPharmaceuticals	0.00%	0.00%	0.00%	0.00%	+0.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.85	Moderate Buy	$33.27	328.22% Upside
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	134.95% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	135.70% Upside
SCPH scPharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SCPH, MNKD, ALMS, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
9/1/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	41.82	N/A	N/A	$2.88 per share	2.70
GLUE Monte Rosa Therapeutics	$123.67M	8.37	N/A	N/A	$3.58 per share	3.39
MNKD MannKind	$393.63M	2.89	$0.06 per share	57.85	($0.17) per share	-20.82
SCPH scPharmaceuticals	$49.97M	6.05	N/A	N/A	$0.27 per share	21.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	-11.21%	-6.31%	11/4/2026 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	N/A

Latest SCPH, MNKD, ALMS, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
MNKD MannKind	N/A	1.72	1.41
SCPH scPharmaceuticals	N/A	3.85	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
GLUE Monte Rosa Therapeutics	79.96%
MNKD MannKind	49.55%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
GLUE Monte Rosa Therapeutics	6.40%
MNKD MannKind	2.60%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable

SCPH, MNKD, ALMS, and GLUE Headlines

Recent News About These Companies

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of ...

June 24, 2026 | stockhouse.com

MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's Changed

May 8, 2026 | finance.yahoo.com

scPharmaceuticals Inc. Common Stock (SCPH)

April 17, 2026 | nasdaq.com

MannKind initiated with a Buy at Truist

November 24, 2025 | msn.com

MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion

November 8, 2025 | finance.yahoo.com

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

November 5, 2025 | msn.com

MannKind outlines FUROSCIX market expansion and Afrezza pediatric launch strategy following record $82M Q3 revenue

November 5, 2025 | msn.com

MannKind completes acquisition of scPharmaceuticals

October 7, 2025 | msn.com

scPharmaceuticals Completes Merger and Delists from Nasdaq

October 7, 2025 | msn.com

scPharmaceuticals Issues Promissory Note to MannKind

September 25, 2025 | msn.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

September 16, 2025 | businesswire.com

Corstasis scores FDA nod for nasal spray treatment, touts sales potential

September 15, 2025 | fiercepharma.comF

MannKind diversifies pipeline with $360M buy

September 2, 2025 | pacbiztimes.comP

H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)

August 31, 2025 | finance.yahoo.com

scPharmaceuticals downgraded to Hold from Buy at Maxim

August 26, 2025 | msn.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...

August 26, 2025 | tmcnet.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

August 26, 2025 | businesswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

August 26, 2025 | globenewswire.com

scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum

August 25, 2025 | msn.com

CT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M deal

August 25, 2025 | hartfordbusiness.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, MNKD, ALMS, and GLUE Company Descriptions

Alumis NASDAQ:ALMS

$7.77 -0.05 (-0.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.87 +0.10 (+1.34%)

As of 09/18/2026 07:57 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$12.13 -0.47 (-3.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.24 +0.11 (+0.95%)

As of 09/18/2026 07:30 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

MannKind NASDAQ:MNKD

$3.54 -0.04 (-1.12%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.59 +0.05 (+1.36%)

As of 09/18/2026 07:59 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

scPharmaceuticals NASDAQ:SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCPH, MNKD, ALMS, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCPH, MNKD, ALMS, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCPH, MNKD, ALMS, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, MNKD, ALMS, and GLUE Company Descriptions

Alumis NASDAQ:ALMS

Monte Rosa Therapeutics NASDAQ:GLUE

MannKind NASDAQ:MNKD

scPharmaceuticals NASDAQ:SCPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCPH, MNKD, ALMS, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCPH, MNKD, ALMS, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCPH, MNKD, ALMS, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, MNKD, ALMS, and GLUE Company Descriptions

Alumis NASDAQ:ALMS

Monte Rosa Therapeutics NASDAQ:GLUE

MannKind NASDAQ:MNKD

scPharmaceuticals NASDAQ:SCPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools